Blood Diseases and Public Health
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Hematology and Immunology".
Deadline for manuscript submissions: closed (10 December 2023) | Viewed by 1805
Special Issue Editors
2. Department of Cellular and Molecular Pathology, "Stefan S. Nicolau Institute of Virology", 030304 Bucharest, Romania
Interests: myeloid neoplasms; molecular basis; genetic predisposition; non-invasive biomarkers; targeted therapies
Interests: myeloid neoplasms; molecular basis; genetic predisposition; non-invasive biomarkers; targeted therapies; hematologic diseases
Special Issue Information
Dear Colleagues,
Hematological malignancies represent a heterogeneous group of cancers that originate in bone-marrow-derived cells. These distinct neoplastic diseases are the fifth most common type of cancer, with about 1.24 million new cases diagnosed annually worldwide. Their impact on global mortality is substantial, accounting for more than 7% of cancer deaths worldwide.
According to the classification provided by the World Health Organization in 2022, more than 100 blood cancer subtypes are currently described. The main categories of hematological cancers include leukemias, lymphomas, multiple myeloma, as well as myeloproliferative neoplasms (MPN), myelodysplastic neoplasms (MDS), and diseases with overlapping features of myeloproliferation and dysplasia (MDS/MPN). They are characterized by various clinical, histopathologic, and genetic patterns that influence prognosis and therapeutic response.
Due to the illness-related complications and the side effects of intensive therapeutic protocols, with infections being a frequent problem, patients diagnosed with a type of blood cancer often require prolonged and expensive hospitalization.
New therapeutic approaches, including targeted therapy drugs, become available either as an approved treatment option or in clinical trials for patients with hematological malignancies, aiming to improve the survival rate and increase the quality of life.
We invite specialists in the field of hematology to submit original research articles or reviews concerning the advances in the diagnosis, prognostication, treatment, and monitoring of blood cancers.
Dr. Cristina Mambet
Prof. Dr. Ana Maria Vladareanu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
-
molecular landscape of hematological malignancies
- genomic and proteomic biomarkers for risk stratification and personalized treatment
- new pharmacological approaches in blood cancer therapy
- diagnostic and therapeutic challenges in particular types of hematological cancers
- the role of chronic inflammation in blood cancers
- familial blood cancers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
